Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-CVac with Pyrimethamine or Chloroquine in Mali
NCT03952650Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PfSPZ Challenge in malaria (13 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Positive Sensitive Blood Smear (sBS), Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs) and 1 more. Started May 2019; status: completed.
02
Drugs
PfSPZ Challenge
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03952650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952650.